SCHEMBL4549008

SCHEMBL4549008

COc1cc2c(Oc3ccc4c(C(=O)Nc5cccc(Cl)c5)cccc4c3F)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.65
FLT3 P36888 3/20 0.64
MET P08581 17/20 0.61
INSR P06213 2/20 0.58
PLK4 O00444 1/20 0.58
STK25 O00506 1/20 0.58
CIT O14578 1/20 0.58
AURKA O14965 1/20 0.58
CHUK O15111 1/20 0.58
MUSK O15146 1/20 0.58
EPHB6 O15197 1/20 0.58
MAPK13 O15264 1/20 0.58
MAP3K13 O43283 1/20 0.58
DAPK3 O43293 1/20 0.58
MAP3K7 O43318 1/20 0.58
RIPK2 O43353 1/20 0.58
JAK2 O60674 1/20 0.58
ROCK2 O75116 1/20 0.58
PAK3 O75914 1/20 0.58
CDKL5 O76039 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747111 0.94 KDR (0.75) KDRFLT3METINSRPLK4
SCHEMBL4549007 0.93 FLT3 (0.75) KDRFLT3METINSRPLK4
SCHEMBL2747397 0.88 KDR (0.75) KDRFLT3METAURKALCK
SCHEMBL2748274 0.87 AXL (0.64) KDRFLT3METINSRPLK4
SCHEMBL4548999 0.87 KDR (0.85) KDRMETAURKALCKCSF1R
SCHEMBL4548967 0.86 AXL (0.65) KDRFLT3METINSRPLK4
SCHEMBL2747696 0.85 MET (0.67) KDRFLT3METINSRPLK4
SCHEMBL4548851 0.85 FLT3 (0.71) KDRFLT3METINSRPLK4
SCHEMBL2746906 0.83 MET (0.65) KDRFLT3METINSRPLK4
SCHEMBL5755526 0.82 MET (0.63) KDRFLT3METINSRPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885FLT3 56/4885MET 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.